Onward Medical NV ONWD

AMS: ONWD | ISIN: NL0015000HT4   19/04/2024
5,080 EUR (-4,51%)
(-4,51%)   19/04/2024

11 april 2024 · ONWARD® Medical Announces Publication of Full Year 2023 Financial Results and Business Update Webcast · Persbericht

9 april 2024 · Stifel Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 12.00 · Persbericht

2 april 2024 · ONWARD® Medical Submits De Novo Application to FDA for its ARC-EX® System · Persbericht

25 maart 2024 · ONWARD® Medical Publishes Closing of Accelerated Bookbuild Offering and Public Offering in France · Persbericht

21 maart 2024 · ONWARD® Medical Publishes Prospectus for Listing of New Shares · Persbericht

21 maart 2024 · ONWARD® Medical Successfully Raises €20 Million in a Capital Increase by Way of an Accelerated Bookbuild Offering and by Way of a Public Offering in France · Persbericht

21 maart 2024 · ONWARD® Medical Lève avec Succès 20 millions d'euros dans le cadre d'une Augmentation de Capital par le biais d'une Procédure de Construction Accélérée d'un Livre d'Ordres et d'une Offre au Public en France · Persbericht

20 maart 2024 · ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option · Persbericht

20 maart 2024 · ONWARD® Medical Launches Capital Increase by Way of an Accelerated Bookbuild Offering and of a Public Offering in France for an Indicative Amount of EUR 15 Million, with an Up to EUR 5 Million Upsize Option · Persbericht

20 maart 2024 · ONWARD® Medical Lance une Augmentation de Capital par le Biais d'une Procédure de Construction Accélérée d'un Livre d'Ordres et le Biais d'une Offre au Public en France d'un Montant Indicatif de 15 millions d'euros avec l’Option de Lever j · Persbericht

18 maart 2024 · ONWARD® Medical Successfully Completes Benchmark Testing on Path to Commercialize ARC-EX® System · Persbericht

15 maart 2024 · ONWARD® Medical Reaffirms Guidance, Shares 2024 Strategic Priorities, and Releases Unaudited Q4 Financial Highlights · Persbericht

15 maart 2024 · ONWARD renforce son management avec des nominations clés dans le domaine clinique et réglementaire et en marketing · Persbericht

15 maart 2024 · ONWARD versterkt management met kernfuncties in Klinische & Regelgevende en Marketingafdelingen · Persbericht

11 maart 2024 · ONWARD® Medical Accepted to New US FDA TAP Program for Development of its ARC-BCI™ System · Persbericht

29 februari 2024 · ONWARD® Medical Awarded 10th Breakthrough Device Designation for Brain-Computer Interface (BCI) from US FDA · Persbericht

9 februari 2024 · KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share · Persbericht

7 februari 2024 · Onward® Medical Announces Presentation At Biocapital Europe · Persbericht

25 januari 2024 · ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS) · Persbericht

22 januari 2024 · ONWARD® to Participate in Basel Healthtech Conference 2024 · Persbericht

Mijn selecties